{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:05:11Z","timestamp":1789693511244,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T22:25:19Z","timestamp":1786141519000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Factors associated with non-completion of gynecological cancer clinical trials"],"prefix":"10.1016","volume":"212","author":[{"given":"Paige","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran A.","family":"Kanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuva","family":"Vidwans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Donneyong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E.","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle P.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Sinnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.08.003_bb0005","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J. Glob. Health"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0010","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0015","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.22.01826","article-title":"Population, clinical, and scientific impact of National Cancer Institute\u2019s National Clinical Trials Network Treatment Studies","volume":"41","author":"Unger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0020","author":"US National Library of Medicine"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0025","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.19.00151","article-title":"Hysterectomy-corrected uterine Corpus Cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of Nonendometrioid cancers","volume":"37","author":"Clarke","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0030","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2007.09.022","article-title":"Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer","volume":"108","author":"Kim","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0045","article-title":"Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors","volume":"17","author":"Su","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0050","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-022-00703-3","article-title":"Machine learning prediction of clinical trial operational efficiency","volume":"24","author":"Wu","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0075","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1186\/s13063-021-05818-0","article-title":"Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada","volume":"22","author":"Briel","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0080","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1002\/cam4.5385","article-title":"Early termination of oncology clinical trials in the United States","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100843","article-title":"Trial-level factors affecting accrual and completion of oncology clinical trials: a systematic review","volume":"24","author":"Hauck","year":"2021","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-15361-9","article-title":"Characteristics and potential predictors of prematurely terminated interventional clinical trials for ovarian cancer in the ClinicalTrials.gov database","volume":"26","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0095","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1038\/s41598-021-82840-x","article-title":"Predictive modeling of clinical trial terminations using feature engineering and embedding learning","volume":"11","author":"Elkin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrclinonc.2015.194","article-title":"The changing landscape of phase I trials in oncology","volume":"13","author":"Wong","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/bimj.201800250","article-title":"A multistate model for early decision-making in oncology","volume":"62","author":"Beyer","year":"2020","journal-title":"Biom. J."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0110","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology - when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0115","article-title":"Recent innovations in adaptive trial designs: a review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J Clin Transl Sci."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10651","article-title":"Association of the Coronavirus Disease 2019 (COVID-19) outbreak with enrollment in Cancer clinical trials","volume":"3","author":"Unger","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13063-023-07277-1","article-title":"Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries","volume":"24","author":"McDonald","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0130","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-friends of Cancer research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0135","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of Cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0140","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41598-024-53211-z","article-title":"Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials","volume":"14","author":"Markey","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv324","article-title":"Predicting low accrual in the National Cancer Institute\u2019s cooperative group clinical trials","volume":"108","author":"Bennette","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and Meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to Cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","article-title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","volume":"7","author":"Mills","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013482","article-title":"Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006-2015","volume":"7","author":"Baldi","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/cts.12296","article-title":"Developing common metrics for the clinical and translational science awards (CTSAs): lessons learned","volume":"8","author":"Rubio","year":"2015","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0170","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.2019.9892","article-title":"Harms from uninformative clinical trials","volume":"322","author":"Zarin","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473590","article-title":"Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials","volume":"45","author":"Azenkot","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0180","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2024.28047","article-title":"Manual vs AI-assisted prescreening for trial eligibility using large language models-a randomized clinical trial","volume":"333","author":"Unlu","year":"2025","journal-title":"Jama"},{"key":"10.1016\/j.ygyno.2026.08.003_bb0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/2168479018782885","article-title":"Evaluating the completeness of ClinicalTrials.gov","volume":"53","author":"Stergiopoulos","year":"2019","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0190","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1017\/cts.2025.9","article-title":"The importance of ClinicalTrials.gov in informing trial design, conduct, and results","volume":"9","author":"Califf","year":"2025","journal-title":"J. Clin. Transl. Sci."},{"key":"10.1016\/j.ygyno.2026.08.003_bb0195","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/003335490812300415","article-title":"Increasing transparency at the FDA: the impact of the FDA amendments act of 2007","volume":"123","author":"Wood","year":"2008","journal-title":"Public Health Rep."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:41:55Z","timestamp":1789692115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0090825826020937"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with non-completion of gynecological cancer clinical trials","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}